Helixmith Co Ltd
KOSDAQ:084990
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tibet Aim Pharm Inc
SZSE:002826
|
CN |
|
BHG Group AB
STO:BHG
|
SE |
|
Escalade Inc
NASDAQ:ESCA
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (43.9), the stock would be worth ₩-11 981.1 (244% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -30.5 | ₩8 320 |
0%
|
| Industry Average | 43.9 | ₩-11 981.1 |
-244%
|
| Country Average | 12.5 | ₩-3 426.1 |
-141%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
H
|
Helixmith Co Ltd
KOSDAQ:084990
|
383.1B KRW | -30.5 | -880.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 20 | 86.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 14 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 15 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 22 | 28.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR | 42.4 | 38.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.6 | 31.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.8 |
| Median | 12.5 |
| 70th Percentile | 23.2 |
| Max | 13 874.5 |
Other Multiples
Helixmith Co Ltd
Glance View
Helixmith Co., Ltd. engages in the development and sale of bio and natural substances. The company is headquartered in Seoul, Seoul. The company went IPO on 2005-12-29. The firm operates its business through two segments. The Natural Products Business segment develops and sells raw materials for functional materials and health functional foods such as Alex, Murphine, and Nimosin. The New Biopharmaceutical Business segment develops diabetic neuropathy treatment, diabetic ischemic foot ulcer, amyotrophic lateral sclerosis treatment, ischemic heart disease, and anticancer treatment.
